About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

TERMINATED

The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia

NCT01010256•University of Arkansas

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Chronic Myelomonocytic Leukemia

Locations

1

United States

Locations (1)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Key Dates

Start Date

November 1, 2009

Primary Completion Date

October 3, 2019

Completion Date

October 3, 2019

Last Updated

February 7, 2020

Related Studies

RECRUITINGPhase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424

AML (Acute Myelogenous Leukemia)Acute Lymphoid Leukemia (ALL)+9 more

RECRUITINGPhase 1

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676

High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)+2 more

RECRUITINGPhase 1/2

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

NCT06523556

Atypical Chronic Myeloid LeukemiaChronic Myelomonocytic Leukemia+6 more

RECRUITINGPhase 1

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

NCT06543381

Acute Myeloid LeukemiaChronic Myelomonocytic Leukemia+1 more

RECRUITINGPhase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633

Acute LeukemiaAcute Lymphoblastic Leukemia+17 more

RECRUITINGPhase 2

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

NCT07046078

Acute Leukemia of Ambiguous LineageAcute Myeloid Leukemia+2 more

View all related studies

Sponsors

Lead Sponsor

University of Arkansas

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 7, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions